Systemic interferon type I and type II signatures in primary Sjögren’s syndrome reveal differences in biological disease activity

Abstract

Systemic IFN activation is associated with higher activity only in the ESSDAI biological domain but not in other domains or the total score. Our data raise the possibility that the ESSDAI biological domain score may be a more sensitive endpoint for trials targeting either IFN pathway.